LEADER 05277nam 2200637Ia 450 001 9910831001303321 005 20170810193238.0 010 $a1-282-30250-7 010 $a9786612302503 010 $a3-527-62790-1 010 $a3-527-62791-X 035 $a(CKB)1000000000799944 035 $a(EBL)481853 035 $a(OCoLC)587404927 035 $a(SSID)ssj0000334497 035 $a(PQKBManifestationID)11254735 035 $a(PQKBTitleCode)TC0000334497 035 $a(PQKBWorkID)10271515 035 $a(PQKB)10612677 035 $a(MiAaPQ)EBC481853 035 $a(PPN)190136170 035 $a(EXLCZ)991000000000799944 100 $a20090504d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAIDS and tuberculosis$b[electronic resource] $ea deadly liaison /$fed. by Stefan H. E. Kaufmann and Bruce D. Walker 210 $aWeinheim $cWiley-VCH$d2009 215 $a1 online resource (322 p.) 225 1 $aInfection biology handbook series 300 $aDescription based upon print version of record. 311 $a3-527-32270-1 327 $aAIDS and Tuberculosis: A Deadly Liaison; Contents; Preface; List of Contributors; Part One: Immunology and Vaccination Strategies for AIDS and TB; 1 HIV Immunology and Prospects for Vaccines; 1.1 Introduction; 1.2 Challenges for HIV Vaccine Design; 1.3 What Immune Responses will be Required for an Effective AIDS Vaccine?; 1.3.1 Cytotoxic T Lymphocytes; 1.3.2 Neutralizing Antibodies; 1.3.3 CD4+ T Helper Cells; 1.3.4 Natural Killer Cells; 1.4 Models of Successful Vaccination?; 1.5 Human Trials of AIDS Vaccines; 1.5.1 Antibody-Based Vaccination; 1.5.1.1 VaxGen Trial of AIDSVax 327 $a1.5.2 T Cell-Based Vaccination1.5.2.1 The STEP Study; 1.6 Recent Advances in Animal Models: Reasons for Optimism; 1.6.1 Success against Heterologous Challenge; 1.6.2 Heterologous rAd26 Prime/rAd5 Boost Vaccine Regimen; 1.6.3 Induction of Effector Memory T-Cell Responses at Viral Entry Sites; 1.7 The Current Vaccine Pipeline; 1.7.1 DNA; 1.7.2 Adenovirus; 1.7.3 Peptides; 1.7.4 Bacillus Calmette-Gue?rin; 1.7.5 Listeria and Other Bacterial Vectors; 1.7.5.1 Listeria monocytogenes; 1.7.5.2 Salmonella enterica; 1.7.5.3 Shigella; 1.7.6 Canarypox; 1.7.7 Adeno-Associated Virus 327 $a1.8 Conclusions and Future DirectionsReferences; 2 Immune Response to Tuberculosis as a Basis for Rational Vaccination Strategies; 2.1 Introduction; 2.2 Clinical Aspects of TB; 2.3 Immune Response to TB: Innate Immunity; 2.4 Adaptive Immunity; 2.4.1 T-Cell Subsets; 2.4.2 T-Cell Activation; 2.5 Cytokines as Mediators of Immune Function; 2.5.1 IL-12 Family of Cytokines; 2.5.2 Tumor Necrosis Factor; 2.6 Vaccines against TB; 2.6.1 From the Past to the Present; 2.6.2 The Future; 2.6.2.1 Goals of Vaccination; 2.6.2.2 Vaccination Strategies; 2.6.2.3 Targets for Vaccination; 2.7 Biomarkers 327 $a2.7.1 Immunologic2.7.2 Transcriptomics; 2.7.3 Proteomics; 2.7.4 Metabolomics; 2.8 Concluding Remarks; References; 3 BCG Vaccination in the HIV+Newborn; 3.1 Bacillus Calmette-Gu erin (BCG) and its Efficacy in Healthy Infants; 3.2 Adverse Events Caused by BCG in Healthy Infants; 3.3 Specific Immunity Induced by BCG in Healthy Infants; 3.4 Efficacy of BCG to Prevent TB in HIV-Infected Infants; 3.5 Adverse Effects Caused by BCG in HIV-Infected Infants not Receiving Antiretroviral Therapy; 3.6 BCG Immune Reconstitution Inflammatory Syndrome (BCG-IRIS) 327 $a3.7 Management of BCG Disease in HIV-Infected Infants3.8 Specific Immunity Induced by BCG in HIV-Infected Infants; 3.9 Weighing up the Evidence: Should BCG be given to HIV-Infected or HIV-Exposed Infants?; 3.10 How Can We Protect HIV-Infected Infants Against TB, if BCG is Not Given?; 3.11 BCG Vaccination of HIV-Exposed, Uninfected Infants; 3.12 Conclusions; References; Part Two: Drugs; 4 HIV/AIDS Drugs; 4.1 Introduction; 4.2 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs); 4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); 4.4 HIV Protease Inhibitors 327 $a4.5 Newer Classes: Entry Inhibitors and Integrase Inhibitors 330 $aProviding the latest information on preventive, diagnostic and therapeutic aspects of tuberculosis and AIDS, this is the only book to place a major emphasis on the increasing coexistence of these two life-threatening diseases in individuals.Edited by outstanding scientists in the field, this ready reference is divided into three main sections covering immunology and vaccination strategies, drugs, and clinical issues.Timely reading for microbiologists, virologists, bacteriologists, immunologists, and pathophysiologists, as well as for the pharmaceutical and biotechnological industries. 410 0$aInfection biology handbook series. 606 $aAIDS (Disease)$xComplications 606 $aTuberculosis 615 0$aAIDS (Disease)$xComplications. 615 0$aTuberculosis. 676 $a616.9792 676 $a616.9792 20 701 $aKaufmann$b S. H. E$g(Stefan H. E.)$042605 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910831001303321 996 $aAIDS and tuberculosis$94048683 997 $aUNINA